Analyst Reco. Lipocine Inc.

Equities

LPCN

US53630X2036

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-20 EDT			5-day change	1st Jan Change
7.74 ^USD	+7.80%		-5.38%	+177.42%

06-10	Lipocine Inc. Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late-Breaking Session at EASL Congress 2024	CI
05-09	Earnings Flash (LPCN) LIPOCINE Reports Q1 Revenue $7.6M	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

LIPOCINE : HC Wainwright Adjusts Lipocine's Price Target to $3.50 From $2.50, Keeps Buy Rating	21-08-26	MT
LIPOCINE : Cantor Fitzgerald Starts Lipocine at Overweight With $3 Price Target	21-06-24	MT
LIPOCINE : Ladenburg Thalmann Adjusts Lipocine's Price Target to $2.50 From $3, Maintains Buy Rating	21-05-27	MT
LIPOCINE : HC Wainwright Adjusts Price Target for Lipocine to $2.50 From $3, Maintains Buy Rating	21-05-27	MT
LIPOCINE : Ladenburg Thalmann Upgrades Lipocine to Buy From Neutral, $3 Price Target	20-12-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer